EisaiGlobalOnc Profile Banner
Eisai Oncology Medical Profile
Eisai Oncology Medical

@EisaiGlobalOnc

Followers
1K
Following
125
Media
275
Statuses
960

At Eisai Oncology Global Medical Affairs, we are driven to pursue innovative solutions to help address cancers with unmet needs. Guidelines: https://t.co/FYi9zcqV2s

Global
Joined May 2021
Don't wanna be here? Send us removal request.
@EisaiGlobalOnc
Eisai Oncology Medical
14 days
Our team is looking forward to attending the International Liver Cancer Association Annual Conference in Hong Kong and sharing our latest research on advanced hepatocellular carcinoma. Learn more and access additional oncology resources: https://t.co/bGOwNF2VLf #ILCA25
0
0
4
@EisaiGlobalOnc
Eisai Oncology Medical
14 days
Enrollment is now open for our randomized dose optimization study of E7386 in combination with other anticancer drug(s) in patients with endometrial carcinoma.
0
2
3
@EisaiGlobalOnc
Eisai Oncology Medical
22 days
We’ll be attending the International Gynecologic Cancer Society Annual Global Meeting in Cape Town to share our latest research on endometrial and ovarian cancer. We hope to see you there. In the meantime, access additional oncology resources: https://t.co/CLcpN1Y4yk #IGCS2025
0
0
4
@EisaiGlobalOnc
Eisai Oncology Medical
23 days
Continuing our commitment to gynecologic oncology research at #IGCS2025
@EisaiUS
Eisai US
23 days
Our dedication to gynecologic oncology research never stops. We're excited to participate in #IGCS2025 in Cape Town next week, where we'll share additional EC insights with the specialized gynecologic cancer community. Learn more about our presentations: https://t.co/D1DpC7mu9h
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
27 days
People with American Indian and Alaska Native ethnicities have the highest incidences of kidney cancer, followed by Black Americans and Hispanic Americans. At Eisai, we’re driven to deliver solutions to address unmet needs.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
28 days
Between 1990 and 2030, the number of newly diagnosed kidney cancer cases worldwide is expected to more than double. Eisai is committed to exploring new therapies to reach patients in need.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
28 days
What is the mechanism of action (MOA) of an antibody-drug conjugate (ADC)? Learn more about ADCs and how they work from experts in the video below
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
28 days
See our latest Phase 3 results for patients with certain types of advanced renal cell carcinoma (#RCC)
@EisaiUS
Eisai US
29 days
Together with @Merck, we’re pleased to share an update on our latest Phase 3 trial for patients with certain types of advanced renal cell carcinoma (#RCC). Read about the results: https://t.co/Jji7T3ISoh
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
29 days
In one study, fibroblast growth factor receptor (FGFR) pathway aberrations were found to have been implicated in approximately ____% of cancer malignancies. A) 5% B) 7% C) 15% D) 20%
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Hepatocellular carcinoma (HCC) accounts for more than 80% of liver cancer cases in the US, making it the most common form of liver cancer. Eisai’s human health care (hhc) mission is dedicated to raising awareness and exploring treatment options.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Over the last 20+ years, metastatic breast cancer incidences have been rising. The rate is higher among non-Hispanic Black women than women in other US racial and ethnic groups. This Breast Cancer Awareness Month, Eisai remains dedicated to pursuing a cancer-free world for all.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Antibody drug conjugates (ADCs) are beginning to transform the treatment landscape for metastatic breast cancer (mBC). Experts from the breast cancer field discuss this burgeoning treatment option below.
0
0
2
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
We appreciate the opportunity to share our latest research on metastatic breast cancer at the European Society for Medical Oncology (ESMO) Congress in Berlin.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Advancing endometrial carcinoma research through long-term clinical data #ESMO25
@EisaiUS
Eisai US
1 month
We're sharing important long-term follow-up data on endometrial carcinoma at #ESMO25. Visit our poster presentation today to learn about this ongoing research in collaboration with @Merck.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Join us at #ESMO25 to explore the latest developments in #cancer research and care.
@EisaiUS
Eisai US
1 month
Innovation meets collaboration at #ESMO25. We’re honored to join the global oncology community in Berlin as we unite to advance cancer care, sharing meaningful research and engaging in scientific dialogue that drives progress for patients worldwide. Follow along for updates!
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Our dose optimization study is still recruiting, with @dsmgyo as an investigator. The objective of this study is dose optimization of E7386 in combination with other anticancer drug(s) in patients with endometrial carcinoma.
0
1
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Our team is attending the American Conference on Pharmacometrics (ACoP) in Aurora, Colorado, to share our latest research.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Our team is attending the European Society for Medical Oncology (ESMO) Congress in Berlin to share our latest research on renal cell carcinoma. We hope to see you there.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
Experts continue to search for new ways to address unmet needs in metastatic breast cancer (mBC). Watch below to hear some of the leading voices from around the world weigh in on this conversation.
0
0
3
@EisaiGlobalOnc
Eisai Oncology Medical
1 month
On Breast Cancer Awareness Day, and every day, Eisai is dedicated to offering helpful resources, including our Magnolia program, which provides at-home meals, service animals, and more for those living with cancer and the loved ones who care for them.
0
0
4